SLV213 Treatment in Ambulatory COVID-19 Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This Phase 2a trial recruits adult ambulatory patients who have been determined to be COVID-19 positive. The study drug SLV213 will be administered to examine its safety, tolerability and provide assessment of its effect on clinical symptoms of COVID-19. Blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) analysis.
Epistemonikos ID: ec8bb764cab17d1c19d2a6a5a08a868c6e1b8e2b
First added on: Apr 15, 2021